The Role of Direct Oral Anticoagulants in Cancer-Associated Venous Thromboembolism

Patients with cancer are at increased risk for developing venous thromboembolism (VTE) due to a combination of cancer-induced hypercoagulability, endothelial and vessel wall damage, and venous stasis. VTE risk is highest in patients with hematologic malignancies, lung cancer, gastrointestinal cancer...

Full description

Saved in:
Bibliographic Details
Published in:Journal for nurse practitioners 2019-07, Vol.15 (7), p.528-529
Main Authors: Hueftle, Brooke, Kator, Sarah
Format: Article
Language:English
Subjects:
Anticoagulants
Cancer therapies
Chemotherapy
Gastrointestinal cancer
Glycoproteins
Health risk assessment
Lung cancer
Pancreatic cancer
Patient compliance
Thromboembolism
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Patients with cancer are at increased risk for developing venous thromboembolism (VTE) due to a combination of cancer-induced hypercoagulability, endothelial and vessel wall damage, and venous stasis. VTE risk is highest in patients with hematologic malignancies, lung cancer, gastrointestinal cancer, and pancreatic cancer. In addition, treatment-related factors further increase VTE risk. Cytotoxic chemotherapy can induce interleukin release promoting coagulation, and use of exogenous hormone replacement therapy (eg, tamoxifen) and immunomodulating agents (eg, lenalidomide) increase the risk of VTE through increased platelet aggregation. Other risk factors, including prechemotherapy platelet and leukocyte count, hemoglobin level, and body mass index, can be used to predict chemotherapy-associated thrombosis.
ISSN:1555-4155
1878-058X
DOI:10.1016/j.nurpra.2019.02.015